JP2022058873A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022058873A5 JP2022058873A5 JP2022015514A JP2022015514A JP2022058873A5 JP 2022058873 A5 JP2022058873 A5 JP 2022058873A5 JP 2022015514 A JP2022015514 A JP 2022015514A JP 2022015514 A JP2022015514 A JP 2022015514A JP 2022058873 A5 JP2022058873 A5 JP 2022058873A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- compound
- subject
- use according
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 10
- 229940079593 drug Drugs 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000003176 fibrotic effect Effects 0.000 claims 3
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims 2
- 238000011260 co-administration Methods 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 229940069428 antacid Drugs 0.000 claims 1
- 239000003159 antacid agent Substances 0.000 claims 1
- 229960001340 histamine Drugs 0.000 claims 1
- 229940126409 proton pump inhibitor Drugs 0.000 claims 1
- 239000000612 proton pump inhibitor Substances 0.000 claims 1
- 229960004157 rabeprazole Drugs 0.000 claims 1
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023118969A JP2023139157A (ja) | 2016-11-30 | 2023-07-21 | 抗線維化療法を投与する方法 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662428163P | 2016-11-30 | 2016-11-30 | |
| US62/428,163 | 2016-11-30 | ||
| US201662432425P | 2016-12-09 | 2016-12-09 | |
| US62/432,425 | 2016-12-09 | ||
| JP2019524383A JP2020502054A (ja) | 2016-11-30 | 2017-11-29 | 抗線維化療法を投与する方法 |
| PCT/US2017/063549 WO2018102323A1 (en) | 2016-11-30 | 2017-11-29 | Methods of administering anti-fibrotic therapy |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019524383A Division JP2020502054A (ja) | 2016-11-30 | 2017-11-29 | 抗線維化療法を投与する方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023118969A Division JP2023139157A (ja) | 2016-11-30 | 2023-07-21 | 抗線維化療法を投与する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022058873A JP2022058873A (ja) | 2022-04-12 |
| JP2022058873A5 true JP2022058873A5 (enExample) | 2022-11-21 |
| JP7495951B2 JP7495951B2 (ja) | 2024-06-05 |
Family
ID=60655162
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019524383A Pending JP2020502054A (ja) | 2016-11-30 | 2017-11-29 | 抗線維化療法を投与する方法 |
| JP2022015514A Active JP7495951B2 (ja) | 2016-11-30 | 2022-02-03 | 抗線維化療法を投与する方法 |
| JP2023118969A Withdrawn JP2023139157A (ja) | 2016-11-30 | 2023-07-21 | 抗線維化療法を投与する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019524383A Pending JP2020502054A (ja) | 2016-11-30 | 2017-11-29 | 抗線維化療法を投与する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023118969A Withdrawn JP2023139157A (ja) | 2016-11-30 | 2023-07-21 | 抗線維化療法を投与する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11207304B2 (enExample) |
| EP (2) | EP3548025A1 (enExample) |
| JP (3) | JP2020502054A (enExample) |
| KR (3) | KR20190089862A (enExample) |
| CN (1) | CN110087651A (enExample) |
| AU (3) | AU2017366881A1 (enExample) |
| CA (2) | CA3045455A1 (enExample) |
| IL (3) | IL299447A (enExample) |
| MX (3) | MX2019006143A (enExample) |
| TW (2) | TWI826361B (enExample) |
| WO (1) | WO2018102323A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11207304B2 (en) | 2016-11-30 | 2021-12-28 | Genentech, Inc. | Methods of administering anti-fibrotic therapy |
| CN114129517A (zh) * | 2020-09-03 | 2022-03-04 | 苏州爱科百发生物医药技术有限公司 | 一种ak3287制剂及其制备方法和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| KR102373700B1 (ko) * | 2014-04-02 | 2022-03-11 | 인터뮨, 인크. | 항섬유성 피리디논 |
| US11207304B2 (en) | 2016-11-30 | 2021-12-28 | Genentech, Inc. | Methods of administering anti-fibrotic therapy |
-
2017
- 2017-11-29 US US16/465,015 patent/US11207304B2/en active Active
- 2017-11-29 TW TW106141628A patent/TWI826361B/zh active
- 2017-11-29 CA CA3045455A patent/CA3045455A1/en active Pending
- 2017-11-29 CA CA3247781A patent/CA3247781A1/en active Pending
- 2017-11-29 TW TW112145288A patent/TWI891129B/zh active
- 2017-11-29 WO PCT/US2017/063549 patent/WO2018102323A1/en not_active Ceased
- 2017-11-29 KR KR1020197013644A patent/KR20190089862A/ko not_active Ceased
- 2017-11-29 EP EP17812223.0A patent/EP3548025A1/en not_active Withdrawn
- 2017-11-29 AU AU2017366881A patent/AU2017366881A1/en not_active Abandoned
- 2017-11-29 KR KR1020227034429A patent/KR102575344B1/ko active Active
- 2017-11-29 JP JP2019524383A patent/JP2020502054A/ja active Pending
- 2017-11-29 CN CN201780074290.6A patent/CN110087651A/zh active Pending
- 2017-11-29 KR KR1020237029765A patent/KR20230129628A/ko not_active Ceased
- 2017-11-29 IL IL299447A patent/IL299447A/en unknown
- 2017-11-29 MX MX2019006143A patent/MX2019006143A/es unknown
- 2017-11-29 EP EP24206151.3A patent/EP4470624A3/en not_active Withdrawn
-
2019
- 2019-05-06 IL IL266480A patent/IL266480A/en unknown
- 2019-05-27 MX MX2020011766A patent/MX2020011766A/es unknown
- 2019-05-27 MX MX2023003924A patent/MX2023003924A/es unknown
-
2021
- 2021-11-17 US US17/528,537 patent/US11925624B2/en active Active
-
2022
- 2022-01-02 IL IL289544A patent/IL289544B2/en unknown
- 2022-02-03 JP JP2022015514A patent/JP7495951B2/ja active Active
-
2023
- 2023-07-21 JP JP2023118969A patent/JP2023139157A/ja not_active Withdrawn
- 2023-11-10 AU AU2023263548A patent/AU2023263548B2/en active Active
-
2024
- 2024-02-13 US US18/440,652 patent/US12310951B2/en active Active
-
2025
- 2025-09-29 AU AU2025238129A patent/AU2025238129A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6141958B2 (ja) | 増殖性疾患の治療のための併用療法（ベムラフェニブ及びｍｄｍ２阻害剤） | |
| JP2024133474A5 (enExample) | ||
| JP2005506367A5 (enExample) | ||
| JP2020529996A5 (enExample) | ||
| JP2014526503A5 (enExample) | ||
| CN107427502A (zh) | 使用川地匹坦的治疗方法 | |
| JP2022058873A5 (enExample) | ||
| JP2015517523A5 (enExample) | ||
| TW202327597A (zh) | 一種ezh2抑制劑用於製備治療t細胞淋巴瘤的藥物的用途 | |
| EP4520394A3 (en) | New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases | |
| CN104039148A (zh) | 组合als疗法 | |
| WO2016061253A1 (en) | Drug combination to treat melanoma | |
| JPWO2019241442A5 (enExample) | ||
| JPWO2020257671A5 (enExample) | ||
| JP6370801B2 (ja) | 肝疾患または肝障害の治療のための使用および方法 | |
| JP2005513167A5 (enExample) | ||
| BR112020018362A2 (pt) | Composição de glp-1 para tratar obesidade e controle de peso | |
| JP2005526022A5 (ja) | 関節リウマチの処置 | |
| EP3409271B1 (en) | Local anesthetics to facilitate food intake and food retention | |
| WO2024078468A1 (zh) | 二苯乙烯衍生物用于预防和或治疗溃疡的用途 | |
| TW201244732A (en) | Ezatiostat for treating multiple myeloma | |
| JP2021091608A5 (enExample) | ||
| TWI837197B (zh) | 胺基甲酸酯化合物於預防、緩解或治療糖尿病周邊神經病變或化療誘發的周邊神經病變的用途 | |
| CN112533604A (zh) | 用于治疗癌症的组合疗法 | |
| JPWO2020037152A5 (enExample) |